Moreover, we also aimed at developing a drug delivery system with a relatively low burst release and improve the encapsulation efficiency. Our approach to reach this particular goal was to formulate the glycoconjugates as nanoparticles. a-CT was chosen as the model protein since it has been employed previously by us to study the

effect of glycosylation on enzyme stability including in the solid phase [17,18,21,22] and has been formulated as solid nanoparticles by us [24]. In addition, a-CT is an excellent sensor for encapsulation-induced aggregation and inactivation and has been employed by us frequently as model enzyme in s/o/w encapsulation procedures [13,29]. Lactose was covalently attached to a-CT using synthesis conditions adjusted to achieve an average number of lactose molecules bound to the protein of 4 (Lac4-a-CT) Trichostatin A molecular weight and 7 (Lac7-a-CT) since maximum thermodynamic and colloidal stability in solution have been reported for these constructs [18,22]. To test whether we could form nanoparticles using the neo-glycoconjugates, we co-dissolved a-CT and the a-CT glycoconjugates with methyl--cyclodextrin at a 1:4 mass ratio

followed by lyophilization and suspension of the dry powders in ethyl acetate. The particles obtained were subjected to centrifugation and collected as described [24]. SEM images of a-CT lyophilized without MCD show that the powder particles had an irregular shape Adriamycin price and the particle size was in the micrometer range (Fig. 1A). In contrast, co-lyophilization with MCD followed by suspension in ethyl acetate caused a drastic reduction

in particle size for all formulations. Rucaparib molecular weight a-CT nanospheres had a diameter of 115±5▒nm (Fig. 1B), Lac4-a-CT nanospheres one of 248±11▒nm (Fig. 1C), and Lac7-a-CT nanospheres one of 261±4▒nm (Fig. 1D) as determined by dynamic light scattering (Table 1). It was noticeable that the diameter of the particles approximately doubled as a consequence of the glycosylation. Nanoparticle formation did not compromise protein stability. The formation of buffer-insoluble protein aggregates was ≤5% for all the samples regardless of the modification. Furthermore, the residual activity of the samples did not change with exception of Lac7-a-CT for which a 10% drop occurred (Table 1). All samples were subsequently employed to test the stability consequences of their encapsulation in PLGA microspheres. Microspheres were prepared by a s/o/w technique using a-CT nanoparticles (Table 2). The encapsulation efficiency was between 23 and 61% allowing us to perform subsequent stability and release studies. Protein stability during encapsulation in the PLGA microspheres was markedly improved by glycosylation.